Keywords: Progenics, Wyeth, Relistor, Licensing, Opioid induced constipation

Progenics regains global rights to Relistor from Wyeth; will seek new partners

Article | 15 October 2009

USA-based Progenics Pharmaceuticals says it is regaining all worldwide rights to the Relistor (methylnaltrexone) franchise from drug major Wyeth (which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in